Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
EVFM Evofem Biosciences
0.075
-0.007-8.54%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
-57.68% 19.89M -93.91% 2.76M -84.19% 7.73M -84.19% 7.73M
-Cash and cash equivalents
-57.68% 19.89M -93.91% 2.76M -84.19% 7.73M -84.19% 7.73M
Receivables
135.01% 7.3M 51.54% 4.42M 389.67% 6.45M -- 6.45M
-Accounts receivable
135.01% 7.3M 51.54% 4.42M 504.40% 6.45M 504.40% 6.45M
-Notes receivable
-- -- -- -- -- 0 -- --
Inventory
-43.62% 5.95M -40.09% 5.39M 7.15% 7.67M -- --
Prepaid assets
-62.18% 7.19M 36.30% 4.63M -84.71% 2.6M -- --
Restricted cash
-89.60% 1.58M -78.02% 4.17M -77.59% 5.06M -77.59% 5.06M
Other current assets
-- -- -- -- -21.38% 629K -- --
Total current assets
-56.18% 41.91M -73.41% 21.36M -69.16% 30.14M -- 19.24M
Non current assets
Net PPE
-14.50% 10.34M -13.23% 10.51M -0.19% 11.17M -- --
-Gross PPE
-24.60% 10.34M -21.91% 10.51M 8.12% 13.34M -- --
-Accumulated depreciation
-- -- -- -- -88.88% -2.17M -- --
Non current prepaid assets
-- -- -- -- -49.07% 109K -- --
Other non current assets
42.49% 1.22M 224.46% 2.71M 31.18% 1.09M -- --
Total non current assets
-11.82% 11.57M 0.62% 13.21M 1.09% 12.37M -- 0
Total assets
-50.83% 53.47M -63.01% 34.57M -61.34% 42.51M -- 19.24M
Liabilities
Current liabilities
Payables
99.75% 15.39M 115.98% 14.04M -3.05% 10.32M -- --
-accounts payable
99.75% 15.39M 115.98% 14.04M -3.05% 10.32M -- --
Current accrued expenses
-7.70% 6.92M 8.59% 9.75M 87.00% 8.37M -- --
Current debt and capital lease obligation
160.43% 121.83M 108.90% 116.31M 103.40% 111.26M -- --
-Current debt
169.72% 119.51M 114.38% 114.09M 107.84% 108.93M -- --
-Current capital lease obligation
-6.19% 2.32M -9.69% 2.22M 1.83% 2.33M -- --
Other current liabilities
5,493.68% 115.96M 497.55% 9.26M 221.72% 3.07M -- --
Current liabilities
288.69% 265.56M 104.04% 154.47M 78.13% 137.66M 78.13% 137.66M
Non current liabilities
Long term debt and capital lease obligation
-87.52% 3.91M -87.03% 4.06M -85.84% 4.42M -- --
-Long term capital lease obligation
-24.37% 3.91M -27.54% 4.06M -26.63% 4.42M -- --
Preferred securities outside stock equity
-- -- -- 4.14M -- -- -- --
Total non current liabilities
-87.56% 3.91M -73.89% 8.2M -85.88% 4.42M -- -123.17M
Total liabilities
170.05% 269.47M 51.88% 162.67M 30.81% 142.09M -- 14.5M
Shareholders'equity
Share capital
-50.00% 8K -90.00% 1K 59,350.00% 4.76M -- 4.74M
-common stock
-50.00% 8K -90.00% 1K 100.00% 16K -- 0
-Preferred stock
-- 0 -- 0 -- 4.74M -- 4.74M
Retained earnings
-38.74% -1.02B -27.21% -892.57M -31.30% -860.68M -- --
Paid-in capital
7.83% 802.27M 10.35% 759.2M 14.38% 751.26M -- --
Gains losses not affecting retained earnings
-- 1.6M -- 5.27M -- 5.09M -- --
Total stockholders'equity
-2,509.58% -216M -839.29% -128.1M -7,492.35% -99.58M 251.89% 4.74M
Total equity
-2,509.58% -216M -839.29% -128.1M -7,492.35% -99.58M 251.89% 4.74M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion with Explanation--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
CEO: Ms. Saundra Pelletier
Market: Pink Market
Listing Date: 11/20/2014
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist